StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Spyre Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $215.80M, up 21.9% year over year. For fiscal 2025 it was $171.65M, up 5.4% from the year before. Over ten years it grew 31.1% a year on average. The highest annual figure on record is $171.65M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$171.65M+5.4%
FY2024Dec 31, 2024$162.79M+81.9%
FY2023Dec 31, 2023$89.50M+52.8%
FY2022Dec 31, 2022$58.58M+2.6%
FY2021Dec 31, 2021$57.07M-4.3%
FY2020Dec 31, 2020$59.64M-7.7%
FY2019Dec 31, 2019$64.60M+75.9%
FY2018Dec 31, 2018$36.72M+60.9%
FY2017Dec 31, 2017$22.82M+25.8%
FY2016Dec 31, 2016$18.14M+58.4%
FY2015Dec 31, 2015$11.45M+67.7%
FY2014Dec 31, 2014$6.83M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$65.50M+63.2%
Q1 FY2026Mar 31, 2026$60.41M+45.1%
Q4 FY2025Dec 31, 2025$44.64M-11.6%
Q3 FY2025Sep 30, 2025$45.25M+1.1%
Q2 FY2025Jun 30, 2025$40.15M+23.0%
Q1 FY2025Mar 31, 2025$41.62M+19.2%
Q4 FY2024Dec 31, 2024$50.48M+49.9%
Q3 FY2024Sep 30, 2024$44.74M+81.4%
Q2 FY2024Jun 30, 2024$32.64M+87.7%
Q1 FY2024Mar 31, 2024$34.93M+153.5%
Q4 FY2023Dec 31, 2023$33.68M+136.3%
Q3 FY2023Sep 30, 2023$24.66M+105.9%
Q2 FY2023Jun 30, 2023$17.39M+13.1%
Q1 FY2023Mar 31, 2023$13.78M-18.9%
Q4 FY2022Dec 31, 2022$14.25M-15.1%
Q3 FY2022Sep 30, 2022$11.98M-19.4%
Q2 FY2022Jun 30, 2022$15.37M+13.2%
Q1 FY2022Mar 31, 2022$16.98M+43.2%
Q4 FY2021Dec 31, 2021$16.78M+6.5%
Q3 FY2021Sep 30, 2021$14.85M+19.3%
Q2 FY2021Jun 30, 2021$13.58M-19.5%
Q1 FY2021Mar 31, 2021$11.86M-18.6%
Q4 FY2020Dec 31, 2020$15.76M-10.3%
Q3 FY2020Sep 30, 2020$12.45M-30.2%
Q2 FY2020Jun 30, 2020$16.87M+13.9%
Q1 FY2020Mar 31, 2020$14.56M+1.2%
Q4 FY2019Dec 31, 2019$17.57M+48.9%
Q3 FY2019Sep 30, 2019$17.84M+99.8%
Q2 FY2019Jun 30, 2019$14.81M+62.3%
Q1 FY2019Mar 31, 2019$14.39M+109.4%
Q4 FY2018Dec 31, 2018$11.80M+103.7%
Q3 FY2018Sep 30, 2018$8.93M+43.1%
Q2 FY2018Jun 30, 2018$9.12M+56.3%
Q1 FY2018Mar 31, 2018$6.87M+38.8%
Q4 FY2017Dec 31, 2017$5.79M+22.1%
Q3 FY2017Sep 30, 2017$6.24M+15.9%
Q2 FY2017Jun 30, 2017$5.84M–
Q1 FY2017Mar 31, 2017$4.95M–
Q4 FY2016Dec 31, 2016$4.74M–
Q3 FY2016Sep 30, 2016$5.39M–

More Spyre Therapeutics figures

See a number that looks wrong?